Trump's Reclassification of Medical Marijuana Marks a Significant Policy Change
In a notable policy shift, President Trump has reclassified state-licensed medical marijuana as a less-dangerous drug, a change that advocates have long pursued.
Colorado and Virginia Legislatures Push Back Against Drug Affordability Board Restrictions
Legislators in Colorado and Virginia are opposing efforts to limit the powers of prescription drug affordability boards, highlighting a significant debate over drug pricing strategies.
New Medicare Pathway Proposed for Breakthrough Medical Devices by CMS and FDA
Federal regulators are set to unveil a new Medicare coverage pathway aimed at accelerating access to FDA-designated breakthrough medical devices, enhancing treatment options for patients.
RFK Jr. Adjusts Stance on Vaccinations and Pharma Deals
In a recent shift, RFK Jr. has expressed support for vaccinations while also defending his previous secret agreements with pharmaceutical companies.
Future of Medical Radioisotope Supply Discussed at NEA Workshop
The Nuclear Energy Agency (NEA) recently convened a workshop to explore advancements and challenges in the supply of medical radioisotopes.
University of Toronto Researchers Uncover Sustainable Path for Cosmetics Production
A recent discovery by researchers at the University of Toronto reveals that certain bacteria can transform waste into valuable chemicals, potentially transforming the cosmetics industry.
Kennedy Shifts Toward a Moderate Stance on MAHA
In a notable shift, Kennedy is adjusting his approach to MAHA, stepping back from several key issues while still making an impact in health care.
Concerns Emerge as Former Tobacco Executive Takes Senior Role at CDC
The appointment of a former Imperial Brands executive to a senior position at the CDC has sparked concerns about potential tobacco industry influence within the agency.
Robert F. Kennedy Jr. Appears Before Senate HELP Committee
Robert F. Kennedy Jr. is set to testify before the Senate's health care panel today. Viewers can watch the proceedings live as he addresses the committee.
Biotech Update: RevMed, Roche, and Kyverna CAR-T Therapy Insights
Stay informed with the latest developments in the biotech sector, featuring updates on RevMed, Roche, and Kyverna's CAR-T therapy.
Understanding Vibrio: Risks Associated with Coastal Waters and Shellfish
As summer approaches, it's essential to be aware of Vibrio, a bacteria present in coastal waters and raw shellfish, to ensure safe beach outings and seafood consumption.
The MAHA Snack Revolution: Healthier Choices or Just Hype?
The rise of MAHA snacks, from protein-infused Pop-Tarts to avocado-oil chips, suggests a shift towards healthier eating. However, nutrition experts caution that the benefits may be overstated.
Exploring the Complex Narratives Behind Pharmaceutical Innovations
Thomas Goetz emphasizes that each drug represents a broader narrative involving health, medicine, society, and economics.
Celebrating 75 Years of the CDC’s EIS Program: A Legacy of Public Health Leadership
The CDC’s Epidemic Intelligence Service has reached a significant milestone, having trained over 4,300 individuals who are now integral to public health efforts.
Roche Pursues Regulatory Approval for MS Drug Despite Ongoing Safety Concerns
Roche is advancing its experimental multiple sclerosis drug to regulators following successful trials, though significant safety concerns persist.
Mapping the Rose Pangenome: A Step Forward in Breeding Innovation
A recent study has mapped 55,000 genes in roses, which are vital ornamental plants. This research could significantly influence breeding practices, as currently, less than 10% of rose species are utilized.
GOP Senators Stand Firm Against Proposed Cuts to NIH and HHS Reorganization
In a notable move, key Republican senators are likely to oppose President Trump's proposed cuts to the National Institutes of Health and the reorganization of Health and Human Services for the second consecutive year.
Analyzing the U.S. Contribution to Global Health Initiatives
As the leading donor in global health, the U.S. government allocates its budget across several critical program areas, including HIV, tuberculosis, and malaria.
Purdue Pharma's $225 Million Forfeiture Paves the Way for Settlement Finalization
A judge is anticipated to impose a $225 million forfeiture on Purdue Pharma, the maker of OxyContin, facilitating the completion of its settlement with the Justice Department.
Purdue Pharma to Forfeit $225 Million in Settlement with Justice Department
A U.S. judge is anticipated to order Purdue Pharma to forfeit $225 million, marking a significant step in ongoing legal proceedings.